Results 151 to 160 of about 24,646 (191)

Graduated Compression Stockings for Thromboprophylaxis in Orthopaedic and Trauma Surgery: A Rapid Review and Meta-Analysis. [PDF]

J Clin Med
Stengel D, Schnorbus D, Ekkernkamp A, Münzberg M, Schmucker B, El Kassar L, Rohrmann F, Grützner PA.   +7 more
europepmc   +1 more source

Contemporary national trends in the management of admissions for pulmonary embolism. [PDF]

Front Cardiovasc Med
Oltman CG, Cao K, Imam M, Bashir R, Dohad S, Secemsky EA, Moussa ID.   +6 more
europepmc   +1 more source

A Single-Domain VNAR Nanobody Binds with High-Affinity and Selectivity to the Heparin Pentasaccharide Fondaparinux. [PDF]

Int J Mol Sci
Gschwandtner M, Derler R, Talker E, Trojacher C, Gubensäk N, Becker W, Gerlza T, Klaus Z, Stocki P, Walsh FS, Rutkowski JL, Kungl A.   +11 more
europepmc   +1 more source

A Regional Audit on Venous Thromboembolism (VTE) Prophylaxis Compliance and Cultural Considerations in Prescribing Porcine-Derived Low-Molecular-Weight Heparins. [PDF]

Cureus
Mujahid M, Ahmed H, Ahmad S, Mujahid I, Ur-Rehman J, Maheshwari G, Norouzi M, Prudon B.   +7 more
europepmc   +1 more source

Thrombotic events after vaccination for covid-19 in Italy: a report from the Italian society on thrombosis and haemostasis registry. [PDF]

Intern Emerg Med
Donadini MP, Tarasconi E, Bertù L, Antonucci E, Contino L, De Stefano V, Marcucci R, Palareti G, Russo L, Tiscia GL, Tripodi A, Gresele P, SISET VAX COVID-19 Working Group.   +12 more
europepmc   +1 more source

Risk Factors for Catheter-Related Thrombosis. [PDF]

J Clin Med
La Cava L, Giustivi D, Bartoli A, Meschia A, Cirigliano F, Lanzi T, Tramalloni B, Calloni M, Zappa P, Taino A, Ronzoni G, Foschi A, Giarretta I, Gemma M, Fabiani A, Cogliati C, Gidaro A.   +16 more
europepmc   +1 more source

Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. [PDF]

Clin Appl Thromb Hemost
Adnan Z, Hussain SI, Jalal AA, Shaukat A, Abid E, Burhan M, Ahmed A, Saghir E, Daniyal SM, Shakir S, Samadi A, Raza AA.   +11 more
europepmc   +1 more source

Risk factors for hypotension and technical complications during single-session double-filtration plasmapheresis: a 15-year retrospective study of 1,022 procedures. [PDF]

Ren Fail
Gao C, Ma J, Jing M, Yang Z, Zhu Y, Yu H, Xie J, Chen X, Chen Z.   +8 more
europepmc   +1 more source

Efficient Small-Molecule Reversal Agents for Anticoagulant Fondaparinux. [PDF]

ACS Pharmacol Transl Sci
Carbajo D, Pérez Y, Castelo GF, Prats E, Bujons J, Alfonso I.   +5 more
europepmc   +1 more source

Fondaparinux: an overview

Expert Review of Cardiovascular Therapy, 2009
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Eduard Shantsila
exaly   +4 more sources